[go: up one dir, main page]

PT2695897T - Novo anticorpo anti-receptor de il-23 humano - Google Patents

Novo anticorpo anti-receptor de il-23 humano

Info

Publication number
PT2695897T
PT2695897T PT12767727T PT12767727T PT2695897T PT 2695897 T PT2695897 T PT 2695897T PT 12767727 T PT12767727 T PT 12767727T PT 12767727 T PT12767727 T PT 12767727T PT 2695897 T PT2695897 T PT 2695897T
Authority
PT
Portugal
Prior art keywords
human
receptor antibody
novel anti
novel
antibody
Prior art date
Application number
PT12767727T
Other languages
English (en)
Inventor
Ohori Makoto
Sasaki Takanori
Sato Hiromu
Taguchi Katsunari
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT2695897T publication Critical patent/PT2695897T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT12767727T 2011-04-01 2012-03-30 Novo anticorpo anti-receptor de il-23 humano PT2695897T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011081982 2011-04-01

Publications (1)

Publication Number Publication Date
PT2695897T true PT2695897T (pt) 2019-06-12

Family

ID=46969077

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12767727T PT2695897T (pt) 2011-04-01 2012-03-30 Novo anticorpo anti-receptor de il-23 humano

Country Status (16)

Country Link
US (1) US9556276B2 (pt)
EP (1) EP2695897B1 (pt)
JP (1) JP5971238B2 (pt)
KR (1) KR20140032392A (pt)
CN (2) CN103459426B (pt)
AR (1) AR085824A1 (pt)
BR (1) BR112013024923A2 (pt)
CA (1) CA2831751A1 (pt)
EA (1) EA026119B1 (pt)
ES (1) ES2728438T3 (pt)
MX (1) MX347955B (pt)
PL (1) PL2695897T3 (pt)
PT (1) PT2695897T (pt)
TR (1) TR201908197T4 (pt)
TW (1) TW201249867A (pt)
WO (1) WO2012137676A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2821416T (pt) * 2012-02-28 2018-12-14 Astellas Pharma Inc Anticorpo de recetor il-23 anti- humano inovador
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
WO2017156488A2 (en) 2016-03-10 2017-09-14 Acceleron Pharma, Inc. Activin type 2 receptor binding proteins and uses thereof
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用
CN116948031A (zh) * 2021-10-13 2023-10-27 浙江博锐生物制药有限公司 抗il-23r抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1994020632A1 (en) 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anti-hiv monoclonal antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101675076B (zh) * 2007-02-28 2013-09-18 默沙东公司 工程化的抗il-23r抗体
US20110158992A1 (en) 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment

Also Published As

Publication number Publication date
JP5971238B2 (ja) 2016-08-17
JPWO2012137676A1 (ja) 2014-07-28
EA201391453A1 (ru) 2014-01-30
CA2831751A1 (en) 2012-10-11
US20140275490A1 (en) 2014-09-18
MX2013011414A (es) 2014-04-14
PL2695897T3 (pl) 2019-08-30
EP2695897A4 (en) 2015-03-18
EP2695897A9 (en) 2015-10-07
TR201908197T4 (tr) 2019-06-21
ES2728438T3 (es) 2019-10-24
EP2695897B1 (en) 2019-05-01
BR112013024923A2 (pt) 2016-11-22
MX347955B (es) 2017-05-16
TW201249867A (en) 2012-12-16
CN104817641B (zh) 2018-06-26
AR085824A1 (es) 2013-10-30
CN103459426B (zh) 2015-05-13
US9556276B2 (en) 2017-01-31
CN104817641A (zh) 2015-08-05
EP2695897A1 (en) 2014-02-12
CN103459426A (zh) 2013-12-18
WO2012137676A1 (ja) 2012-10-11
KR20140032392A (ko) 2014-03-14
EA026119B1 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
ZA201400768B (en) Interleukin-31 monoclonal antibody
IL220404A (en) Antiseptic antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
HK1199038A1 (en) Anti-human xcr1 antibodies xcr1
EP2694539A4 (en) POLYCLONAL ANTIBODY COMPOSITIONS
PT2796550T (pt) Novo anticorpo ctgf anti-humano
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
PL2695897T3 (pl) Nowe przeciwciało przeciwko ludzkiemu receptorowi il-23
PT2821416T (pt) Anticorpo de recetor il-23 anti- humano inovador
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
HK1175486A1 (zh) 抗腫瘤壞死因子α的人源化抗體